Q2 2025 Earnings Call Transcript August 11, 2025 Kymera Therapeutics, Inc. misses on earnings expectations. Reported EPS is $ ...

Dupilumab use for atopic dermatitis and other conditions was associated with an increased risk of incident psoriasis but not psoriatic arthritis.

THREE new treatments for cancer have been approved for use by the NHS in Scotland. The Scottish Medicines Consortium (SMC) ...

Phase 1 healthy volunteer data surpassing Kymera's target product profile, and further validating its oral, dupilumab-like profile KT-621 BroADen Phase 1b trial in ...

Phase 1 healthy volunteer data surpassing Kymera’s target product profile, and further validating its oral, dupilumab-like profile ...

A new international study led by researchers at McMaster University has identified the most effective and safest treatments ...

Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study. AbbVie is currently conducting a Phase 3 clinical ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why ...

A new study highlights the risks of atopic dermatitis flare-ups after discontinuing dupilumab and the likelihood of ...

During the second quarter of 2025, the Company repurchased shares of its common stock and recorded the cost of the shares, or $1.070 billion, as Treasury Stock. As of June 30, 2025, $2.814 billion ...

Sanofi rode the growing sales wave for blockbuster immunology drug Dupixent (dupilumab) in Q2 but reported ...

The biopharmaceutical industry is growing rapidly as a result of significant advancements in biotechnology and drug ...